Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by WatchLearnEarnon Aug 24, 2017 1:29pm
76 Views
Post# 26617753

RE:RE:RE:RE:RE:RE:RE:RE:001

RE:RE:RE:RE:RE:RE:RE:RE:001Great post. Hindsight is deceptive because it doesn't account for future possibilities that would make a prior selling opportunity look short-sighted in comparison as the company progresses their pipeline.

Solid DD, a little luck and a lot of patience are key for me when investing in pharma plays and I own shares in several: Antibe, Biomark, Theralase, Immune Pharma, Briacell, GeneNews, Prometic, Opko, Pernix.

StrikingMoose wrote: The trial has indeed started, if you go back a page or so I linked a sign up page for volunteers looking to participate. 

I have had many of the same feelings as you... wish I had sold back during the spike when they last had a partnership deal or even after the last phase 2 trial. But that is the bane of investing in the stock market. Hating yourself when you look back with perfect hindsight and see the missed opportunities. I like to think that come December, January after the dust has settled and they are searching for a large partner I will look back with hindsight and think "thank god I didn't sell and never look at ATE again".

Let's all hope that these many many months of sitting on our hands in the deep depths of a negative portfolio actually accounts to something.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities